TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11346153
Drug: Descalating dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Descalating dose of interferon-alpha-2a; six million units thrice weekly for 24 weeks followed by 3 MIU 3x for 24 weeks
Study: 11346153
Drug: Interferon-alpha-2a (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2a (3 million units thrice weekly for 24 weeks) plus ribavirin (1,000 mg/day for 12 weeks)
Study: 9214527
Drug: Pramipexole 1.5
Normalized name: pramipexole 1.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 1.5 mg/d
Study: 9214527
Drug: Pramipexole 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 3.0 mg/d
Study: 9214527
Drug: Pramipexole 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 6.0 mg/d
Study: 30381621
Drug: Intravenous l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous l-carnitine
Study: 30381621
Drug: Intravenous branched-chain
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous branched-chain amino acids (BCAA)
Study: 30381621
Drug: Oral l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral l-carnitine supplementation
Study: 30381621
Drug: Conventional agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional agents (lactulose and non-absorbable antibiotics)
Study: 19577936
Drug: metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin plus ADA diet (Met+ADA)
Study: 12458654
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 or 16 mg
Study: 10520057
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) aqueous nasal spray, 200 microg once daily
Study: 10520057
Drug: Levocabastine (LEV)
DrugBank: Levocabastine (DB01106)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocabastine (LEV) nasal spray, 200 microg twice daily
Study: 10520057
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) nasal spray
Study: 8559985
Drug: Misoprostol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (100 mcg intravaginally)
Study: 1791485
Drug: Enalapril (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (an angiotensin converting enzyme inhibitor)
Study: 27426699
Drug: CES with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CES with 200 mg caffeine (CAF2)
Study: 27426699
Drug: CES with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CES with 100 mg caffeine (CAF1)
Study: 22982471
Drug: Enzogenol® pine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol® pine bark extract (480 mg/day for 6 months)
Study: 22982471
Drug: Enzogenol® pine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol® pine bark extract (960 mg/day for 5 weeks)
Study: 22982471
Drug: Enzogenol® pine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol® pine bark extract (single and 14-day repeat dosing in rats and dogs)
Study: 22982471
Drug: Enzogenol® pine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol® pine bark extract (highest dose level in dogs)
Study: 18001210
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg purified isoflavones for 12 weeks
Study: 15533544
Drug: Proactive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telephone support with nicotine patches
Study: 15533544
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (control condition)
Study: 10213125
Drug: Calcitriol (0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5mg twice a day)
Study: 8574714
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice daily for 1 week (Phase 1)
Study: 8574714
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole twice daily for 1 week (Group A)
Study: 8574714
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole daily for 1 week (Group B)
Study: 2192985
Drug: CDDP 50
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 50 mg/mq + alizapride
Study: 2192985
Drug: CDDP 50
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 50 mg/mq + metoclopramide
Study: 2192985
Drug: CDDP 50
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 50 mg/mq + placebo
Study: 393299
Drug: Combined preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparations containing oestrogen and progestogen
Study: 29437489
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message reminders for 30 days
Study: 30388775
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate and potassium bicarbonate fortified with minerals, ingested twice a day over a nine-day training period.
Study: 27468541
Drug: Integrated Traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Traditional Chinese Medicine (TCM) with basic treatment
Study: 22893135
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide 20 mg
Study: 16150197
Drug: Naohuandan (NHD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naohuandan (NHD), 4 capsules each time, 3 times daily for 3 months
Study: 16150197
Drug: Piracetam, 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam, 1.6 g each time, 3 times daily for 3 months
Study: 16150197
Drug: High-dosage NHD
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage NHD
Study: 16150197
Drug: Low-dosage NHD
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage NHD
Study: 16150197
Drug: Model group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model group (no treatment)
Study: 12871256
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once per week for 6 months
Study: 1619099
Drug: Structural family
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural family therapy (n = 20)
Study: 6531953
Drug: Trivalent subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent subunit influenza virus vaccine
Study: 6531953
Drug: Trivalent split
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent split vaccine
Study: 22552505
Drug: Short-term antibiotic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term antibiotic prophylaxis (single dose)
Study: 22552505
Drug: Long-term antibiotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antibiotic prophylaxis (multiple dose)
Study: 19414832
Drug: Stent placement
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent placement and medical treatment (64 patients)
Study: 19414832
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (76 patients)
Study: 19414832
Drug: Stent placement
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent placement with medical treatment
Study: 14971623
Drug: Mainly computer-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly computer-guided self-exposure therapy (FearFighter)
Study: 14971623
Drug: Entirely clinician-guided
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entirely clinician-guided self-exposure therapy
Study: 27647820
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis
Study: 27647820
Drug: Inhaled routes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled routes (smoked or vaporized)
Study: 17803059
Drug: Vazkor 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vazkor 10 mg tablet (test preparation)
Study: 17803059
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tablet of the originator product (reference preparation)
Study: 15217803
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta carotene, 100 microg selenium, and 20 mg zinc)
Study: 11427639
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamins E and C
Study: 7981777
Drug: GH 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 0.1 mg/kg/day (n = 10)
Study: 3057036
Drug: nifedipine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (120 mg/day)
Study: 23624215
Drug: Silymarin (420mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (420mg daily)
Study: 23624215
Drug: Desferrioxamine (40mg/kg/day)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (40mg/kg/day) + Silymarin (420mg daily)
Study: 15550792
Drug: ANP-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP-treated group (n = 13, 0.05 microg/kg/min of synthetic human alpha-ANP administered postoperatively)
Study: 11075311
Drug: Piroxicam-beta-cyclodextrin (PBCD)
Normalized name: piroxicam-beta-cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam-beta-cyclodextrin (PBCD) 20 mg
Study: 11075311
Drug: Piroxicam (Feldene)
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam (Feldene) 20 mg
Study: 8211041
Drug: Sustained-release bezafibrate
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release bezafibrate 400 mg per day for 56 days
Study: 30466131
Drug: Alginate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate therapy (up to 4 times daily for 14 days)
Study: 26945497
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus after 2 months of placebo in polysensitized patients.
Study: 26945497
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus after 2 months of placebo in monosensitized patients.
Study: 26945497
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus in both groups.
Study: 26945497
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus in polysensitized patients.
Study: 20303236
Drug: Fat-free milk
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-free milk (400 mL daily for mild, 600 mL for moderate, 800 mL for severe constipation)
Study: 20303236
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (400 mL for 3 days)
Study: 12085028
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (injection of epinephrine, mechanical removal of clot, coagulation)
Study: 8591078
Drug: FAM chemotherapy
Normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM chemotherapy (5-FU, doxorubicin, mitomycin C) for 1 year (6 cycles)
Study: 103722
Drug: Atropine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5 mg i.v. and 0.5 mg s.c.)
Study: 103722
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion (0.3 mmol/kg.105 min)
Study: 103722
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (0.12 mmol/kg.45 min)
Study: 21385361
Drug: Pedalling daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedalling daily for up to ten minutes, for up to ten working days (experimental group)
Study: 17341317
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol 5 mg after formoterol treatment
Study: 17341317
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 40 mug after formoterol treatment
Study: 17341317
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol 5 mg after placebo treatment
Study: 17341317
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 40 mug after placebo treatment
Study: 14987299
Drug: Heat-inactivated BCG
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated BCG (0.1 mL injection once a week for 4 weeks)
Study: 11251566
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of terbinafine (62.5 mg daily for <20 kg, 125 mg daily for 20-40 kg, 250 mg daily for >40 kg)
Study: 11251566
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of griseofulvin (10 mg/kg daily)
Study: 3440634
Drug: Piretanide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (3 to 12 mg daily for 12 weeks)
Study: 3440634
Drug: Triamterene (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (with and without piretanide) and amiloride in combination with hydrochlorothiazide
Study: 29168570
Drug: Phleum pratense
Normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phleum pratense subcutaneous immunotherapy (Phl‐SCIT)
Study: 28654972
Drug: Electronic pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic pill bottles combined with lottery incentives and social support for medication adherence (1003 patients)
Study: 21621993
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (15% of MIP) for 6 weeks
Study: 18959604
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (n = 125)
Study: 18959604
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (n = 146)
Study: 10194085
Drug: Lederle/Takeda acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis (DTaP) vaccine
Study: 10194085
Drug: Lederle whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle whole‐cell component diphtheria and tetanus toxoids and pertussis (DTP) vaccine
Study: 10194085
Drug: Diphtheria and
Normalized name: Diphtheria and tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria and tetanus toxoids (DT) vaccine
Study: 8546476
Drug: Granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron hydrochloride 3 mg/body administered by intravenous drip before chemotherapy (group A)
Study: 8546476
Drug: Granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron hydrochloride 3 mg/body administered by intravenous drip before chemotherapy (group B)
Study: 1858704
Drug: L-amino acid
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-amino acid diets providing 40 mg leucine.kg-1.d-1
Study: 1858704
Drug: L-amino acid
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-amino acid diets providing 15 mg leucine.kg-1.d-1
Study: 26261865
Drug: Long-term combination
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term combination programme (CP) comprising short-term day-hospital treatment followed by outpatient combined group and individual psychotherapy
Study: 20499131
Drug: 2ME2 NanoCrystal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ME2 NanoCrystal® dispersion (NCD) at 1,500 mg orally four times daily, repeated in 28 day cycles
Study: 11896110
Drug: bioCT (CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: bioCT (CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN alpha-2b three times a week for six cycles)
Study: 9869892
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) therapy
Study: 378017
Drug: Glycopyrrolate (0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.004 mg/kg)
Study: 30945664
Drug: MdHOXs under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MdHOXs under cold treatment
Study: 30945664
Drug: MdHOXs under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MdHOXs under osmotic treatment
Study: 30945664
Drug: MdHOXs under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MdHOXs under high salinity treatment
Study: 30945664
Drug: MdHOXs under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MdHOXs under exogenous ABA treatment
Study: 25424121
Drug: L-carnitine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (4 g/day intravenous)
Study: 22876543
Drug: Pamidronate (PAM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (PAM), 1 mg/kg/day over 2 days
Study: 22876543
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL), 0.025-0.05 mg/kg/day over 2 days every 3-4 months
Study: 18820247
Drug: Pre-magnesium (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-magnesium (bolus of magnesium 50 mg epidurally before induction, followed by infusion of 10 mg h(‐1) until end of surgery)
Study: 18820247
Drug: Post-magnesium (epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-magnesium (epidural saline during the same time periods plus bolus epidural magnesium 50 mg at the end of surgery)
Study: 10514160
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of 20 mg methylprednisolone plus lignocaine
Study: 10514160
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for two weeks
Study: 7671364
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of digoxin (0.39 +/- 0.11 mg/day)
Study: 25785683
Drug: Local lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local lidocaine infiltration (Group L)
Study: 24780643
Drug: Fructose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (60 g)
Study: 10204835
Drug: Fructose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (30 g)
Study: 24780643
Drug: Sucrose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (60 g)
Study: 24780643
Drug: Glucose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (60 g)
Study: 24780643
Drug: Fructose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (60 g) and (30 g)
Study: 19226471
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg once-daily for 12 weeks
Study: 15295223
Drug: Control (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hepatitis B vaccine)
Study: 11266237
Drug: Nebulizer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer therapy
Study: 11266237
Drug: High-dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaler therapy
Study: 3075178
Drug: Calcitonin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (daily 100 MRC of salmon calcitonin intramuscularly)
Study: 3075178
Drug: Cimetidine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (daily 1000 mg orally)
Study: 3075178
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (De‐Nol - four times a day in doses of 5 ml diluted with 15 ml of water)
Study: 27691376
Drug: MOMCare (choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOMCare (choice of brief interpersonal psychotherapy, pharmacotherapy, or both)
Study: 16440422
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole o.d.
Study: 16440422
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole b.i.d.
Study: 16440422
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (30 mg lansoprazole o.d. and 30 mg lansoprazole b.i.d.)
Study: 11151743
Drug: Quercetin aglycone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin aglycone (8 mg, 20 mg, 50 mg)
Study: 11151743
Drug: Rutin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rutin (8 mg, 20 mg, 50 mg)